JP2016516762A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516762A5
JP2016516762A5 JP2016507059A JP2016507059A JP2016516762A5 JP 2016516762 A5 JP2016516762 A5 JP 2016516762A5 JP 2016507059 A JP2016507059 A JP 2016507059A JP 2016507059 A JP2016507059 A JP 2016507059A JP 2016516762 A5 JP2016516762 A5 JP 2016516762A5
Authority
JP
Japan
Prior art keywords
formula
pharmaceutically acceptable
acceptable salt
nalidixic acid
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016507059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516762A (ja
Filing date
Publication date
Priority claimed from GB201306411A external-priority patent/GB201306411D0/en
Priority claimed from GB201306413A external-priority patent/GB201306413D0/en
Application filed filed Critical
Priority claimed from PCT/GB2014/051109 external-priority patent/WO2014167327A1/en
Publication of JP2016516762A publication Critical patent/JP2016516762A/ja
Publication of JP2016516762A5 publication Critical patent/JP2016516762A5/ja
Pending legal-status Critical Current

Links

JP2016507059A 2013-04-09 2014-04-09 炎症性障害の治療 Pending JP2016516762A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201306411A GB201306411D0 (en) 2013-04-09 2013-04-09 Treatment of inflammatory conditions
GB1306411.8 2013-04-09
GB201306413A GB201306413D0 (en) 2013-04-09 2013-04-09 The local treatment of ophthalmic diseases
GB1306413.4 2013-04-09
PCT/GB2014/051109 WO2014167327A1 (en) 2013-04-09 2014-04-09 The treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
JP2016516762A JP2016516762A (ja) 2016-06-09
JP2016516762A5 true JP2016516762A5 (https=) 2017-06-01

Family

ID=50489339

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016507059A Pending JP2016516762A (ja) 2013-04-09 2014-04-09 炎症性障害の治療
JP2016507058A Pending JP2016516761A (ja) 2013-04-09 2014-04-09 炎症性眼疾患の局所治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016507058A Pending JP2016516761A (ja) 2013-04-09 2014-04-09 炎症性眼疾患の局所治療

Country Status (11)

Country Link
US (2) US20160068527A1 (https=)
EP (2) EP2983713A1 (https=)
JP (2) JP2016516762A (https=)
CN (2) CN105431172A (https=)
AU (2) AU2014252808A1 (https=)
CA (2) CA2909111A1 (https=)
GB (2) GB2516137B (https=)
HK (2) HK1221166A1 (https=)
RU (2) RU2015145134A (https=)
WO (2) WO2014167326A1 (https=)
ZA (2) ZA201507718B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104496986A (zh) * 2014-12-12 2015-04-08 苏州亚科化学试剂股份有限公司 萘啶酸的制备方法
JP6474913B2 (ja) * 2015-10-29 2019-02-27 テイカ製薬株式会社 外用剤
US11510931B2 (en) 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
WO2020021035A1 (en) * 2018-07-26 2020-01-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antibiotics for the treatment of immunoglobulin a nephropathy
WO2020163816A1 (en) * 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Quinolin-4-one and 4(1h)-cinnolinone compounds and methods of using same
FI4027983T3 (fi) * 2019-09-11 2026-02-03 Adverum Biotechnologies Inc Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19633480A1 (de) * 1996-08-20 1998-02-26 Bayer Ag Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
ID23053A (id) * 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
DE19729879C2 (de) * 1997-07-11 1999-07-08 Mann Gerhard Chem Pharm Fab Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin
DE19826050A1 (de) * 1998-06-12 1999-12-16 Bayer Ag Verfahren zur Herstellung von Chinolon- und Naphthyridoncarbonsäuren und deren Ester
CN1090959C (zh) * 1999-06-17 2002-09-18 卢世全 一种治疗咳喘病的中、西复方成药及制备方法
US6552020B1 (en) * 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
JP2001342188A (ja) * 2000-03-27 2001-12-11 Takeda Chem Ind Ltd 縮合ピラゾール誘導体、その製造法および用途
JP3648132B2 (ja) * 2000-06-19 2005-05-18 大正薬品工業株式会社 キノロン系抗菌薬液体製剤及びその包装体
WO2003004098A1 (en) * 2001-07-06 2003-01-16 Sucampo Ag Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
CA2928387A1 (en) * 2004-05-03 2005-11-17 Merrimack Pharmaceuticals, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
RS56037B1 (sr) * 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
JP2006028031A (ja) * 2004-07-12 2006-02-02 Ltt Bio-Pharma Co Ltd 経粘膜吸収用薬物封入ナノ粒子
EP2452670A1 (en) * 2004-10-01 2012-05-16 Ramscor, Inc. Conveniently implantable sustained release drug compositions
CA2631773C (en) * 2005-12-02 2022-04-26 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US20080138350A1 (en) * 2006-10-20 2008-06-12 Bennett Michael D Process for use of fluoroquinolones to reduce or modulate inflammation due to eye disease or ophthalmic surgery
CN101129386A (zh) * 2007-07-17 2008-02-27 长治市三宝生化药业有限公司 一种含环丙沙星和地塞米松的局部悬浮滴眼剂
JPWO2009037855A1 (ja) * 2007-09-21 2011-01-06 株式会社日本高度医療研究会 口腔用及び皮膚用組成物
GB0719518D0 (en) * 2007-10-05 2007-11-14 Therapeutics Ltd E Therapy
ES2575954T3 (es) * 2007-10-11 2016-07-04 The Regents Of The University Of California Composiciones y métodos de inhibición de la amidasa ácida hidrolizante de la N-aciletanolamina
MX342183B (es) * 2008-09-09 2016-09-20 Allergan Inc Suspension oftalmica para uso ocular.
EP2346509B1 (en) * 2008-10-07 2020-05-13 Horizon Orphan LLC Inhalation of levofloxacin for reducing lung inflammation
BR112012003453A2 (pt) * 2009-08-19 2019-09-24 Mpex Pharmaceuticals Inc metodo para reduzir taxa de exacerbações agudas de um distúrbio pulmonar: uso de um aerosol de uma solução que comreende levofloxacina ou ofloxacina; método para aumentar o periodo de tempo entre as exaberações agudas de um disturbio pulmonar; uso de um aerossol de uma solução que compreende levofloxacina ou ofloxacina; método para aumentar o período de tempo entre as exacerbações agudas de um distúrbio pulmonar; método para reduzir a taxa de hospitalizações relacionadas ao sistema respiratório de uma população de seres humanos que tem um distúrbio; uso de um aerossol de uma solução que compreende levofloxacina; método, uso ou aerossol.
US20130079353A1 (en) * 2009-12-22 2013-03-28 Karsten Gülow Fluoroquinolones for the treatment and/or prophylaxis of inflammatory diseases
MX346312B (es) * 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.

Similar Documents

Publication Publication Date Title
JP2016516762A5 (https=)
JP2018513107A5 (https=)
JP2016523863A5 (https=)
JP2010132695A5 (https=)
JP2016510012A5 (https=)
JP2004514739A5 (https=)
JP2016534063A5 (https=)
HRP20100104T1 (hr) Kombinacije koje sadrže antimuskarinska sredstva i kortikosteroide
JP2007520508A5 (https=)
RU2015145135A (ru) Лечение воспалительных расстройств
JP2019528316A5 (https=)
JP2017522300A5 (https=)
EP0946175B1 (en) USE OF A COMBINATION OF H+, K+ -ATPase INHIBITORS AND GLUCOCORTICOIDS IN THE TREATMENT OF NASAL POLYPS
JP2007522141A5 (https=)
JP2016516761A5 (https=)
US6599927B2 (en) Use of an H+, K+-ATPase inhibitor in the treatment of Widal&#39;s Syndrome
CN106488770A (zh) 用于治疗copd的福莫特罗和布地奈德的组合
JP2016537432A5 (https=)
JP2019507786A5 (https=)
JP2013536206A5 (https=)
JP2014520874A5 (https=)
JP2011500731A5 (https=)
JP2013518061A5 (https=)
RU2010120806A (ru) Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид
CA2993621A1 (en) Compositions comprising s1p receptor modulators